Valuation: Alector, Inc.

Market Cap 164M 144M 134M 123M 231M 15.82B 235M 1.59B 623M 7.78B 617M 604M 26.9B P/E 2026 *
-1.73x
P/E 2027 * -2.31x
Enterprise Value -82.82M -72.74M -67.64M -62.07M -117M -7.98B -118M -803M -314M -3.92B -311M -304M -13.56B EV / Sales 2026 *
-12.1x
EV / Sales 2027 * -7.08x
Free-Float
86.82%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Alector, Inc.

1 day-0.67%
1 week-1.33%
Current month-26.37%
1 month-20.00%
3 months-38.59%
6 months-23.71%
Current year-5.13%
1 week 1.42
Extreme 1.415
1.55
1 month 1.37
Extreme 1.37
2.14
Current year 1.37
Extreme 1.37
2.74
1 year 1.09
Extreme 1.09
3.4
3 years 0.87
Extreme 0.87
9.06
5 years 0.87
Extreme 0.87
31.24
10 years 0.87
Extreme 0.87
43.32
Manager TitleAgeSince
Chief Executive Officer 71 2013-04-30
Director of Finance/CFO 52 2025-06-19
Chief Tech/Sci/R&D Officer - 2016-12-31
Director TitleAgeSince
Director/Board Member 71 2013-04-30
Director/Board Member 72 2018-09-30
Chairman 77 2023-06-12
Date Insider Type Main position Quantity % Market Cap.
7/9/26 Free

Controller/Auditor

20,000 0.0180%
6/17/26 Free

Director

38,150 0.0344%
6/17/26 Free

Director

38,150 0.0344%
Change 5-day change 1-year change 3-year change Capi.($)
-0.67%-1.33%-15.91%-76.24% 164M
+0.93%+6.97%+59.60%+68.35% 57.28B
-1.92%+6.03%+40.64%+83.42% 54.99B
-0.46%-1.29%+2.86%+428.78% 23.18B
-2.97%-2.35%-22.53%-16.40% 22.59B
-0.36%+5.73%+24.13%-6.24% 20.46B
-1.34%+0.51%+26.03%-29.41% 17.56B
-1.44%+5.67%+38.77%+504.71% 15.67B
-1.30%-5.02%+170.77%+291.37% 14.46B
-0.50%-0.98%+21.43%+180.07% 13.92B
Average -1.00%+1.02%+34.58%+142.84% 24.03B
Weighted average by Cap. -0.87%+2.09%+39.66%+133.35%

Financials

2026 *2027 *
Net sales 6.86M 6.02M 5.6M 5.14M 9.66M 660M 9.81M 66.51M 25.98M 325M 25.74M 25.19M 1.12B 22.88M 20.1M 18.69M 17.15M 32.22M 2.2B 32.72M 222M 86.71M 1.08B 85.9M 84.05M 3.75B
Net income -94.11M -82.66M -76.87M -70.54M -133M -9.06B -135M -913M -357M -4.46B -353M -346M -15.41B -96.62M -84.86M -78.92M -72.42M -136M -9.3B -138M -937M -366M -4.57B -363M -355M -15.82B
Net Debt -247M -217M -202M -185M -348M -23.8B -353M -2.4B -936M -11.7B -928M -908M -40.45B -326M -287M -267M -245M -460M -31.43B -467M -3.17B -1.24B -15.45B -1.23B -1.2B -53.43B
Logo Alector, Inc.
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
Employees
103
Date Price Change Volume
26-07-24 $1.480 -0.67% 325,295
26-07-23 $1.490 -2.61% 607,111
26-07-22 $1.530 -0.65% 333,441
26-07-21 $1.540 +7.69% 499,661
26-07-20 $1.430 -4.67% 463,910
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
1.480USD
Average target price
3.100USD
Spread / Average Target
+109.46%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALEC Stock